Fuller & Thaler Asset Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Fuller & Thaler Asset Management’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-71,991	Closed	-$798K	–	554
2021 Q3	$798K	Buy	+71,991	New	+$905K	0.01%	399
2020 Q4	–	Sell	-8,685	Closed	-$307K	–	544
2020 Q3	$307K	Sell	8,685 -481	-5%	-$20.9K	﹤0.01%	422
2020 Q2	$389K	Buy	+9,166	New	+$618K	0.01%	357

Other funds holding EVFM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Fuller & Thaler Asset Management's EVFM Position: Q4 2021 in Review

Fuller & Thaler Asset Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2021, closing a stake of 71,991 shares — an estimated $798K sold.

Fuller & Thaler Asset Management first reported a position in EVFM in Q2 2020 and held it in 3 quarters. The position peaked at $798K in Q3 2021. 62 funds tracked by Wall St. Rank hold EVFM as of Q4 2021.

Fuller & Thaler Asset Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Fuller & Thaler Asset Management sold 71,991 Evofem Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $798K.
Fuller & Thaler Asset Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
Fuller & Thaler Asset Management's Evofem Biosciences, Inc. Common Stock position peaked at $798K in Q3 2021.
62 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2021.

Based on Fuller & Thaler Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.